Likewise, Vandetanib (B) has been found to be a selective inhibitor that targets the vascular endothelial growth factor receptor (VEGFR) and the EGFR signal transduction pathways for the treatment of breast cancer [5]. This evidence concerns the gene EGFR and breast cancer.